NASDAQ:TROV - TrovaGene News Headlines

$2.11
-0.03 (-1.40 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
$2.09
Now: $2.11
$2.17
50-Day Range
$2.10
MA: $2.56
$3.06
52-Week Range
$2.08
Now: $2.11
$9.65
Volume33,261 shs
Average Volume54,460 shs
Market Capitalization$11.48 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77

Headlines

TrovaGene (NASDAQ TROV) News Headlines

Source:
DateHeadline
Form 8-K Trovagene, Inc. For: Jul 15 - StreetInsider.comForm 8-K Trovagene, Inc. For: Jul 15 - StreetInsider.com
www.streetinsider.com - July 15 at 7:12 PM
Trovagene Commences Non-Deal Investor Roadshow - PRNewswireTrovagene Commences Non-Deal Investor Roadshow - PRNewswire
www.prnewswire.com - July 15 at 7:12 PM
Trovagene Commences Non-Deal Investor RoadshowTrovagene Commences Non-Deal Investor Roadshow
finance.yahoo.com - July 15 at 7:12 PM
TrovaGene Inc (NASDAQ:TROV) Sees Significant Decline in Short InterestTrovaGene Inc (NASDAQ:TROV) Sees Significant Decline in Short Interest
www.americanbankingnews.com - July 12 at 9:19 AM
Form 8-K Trovagene, Inc. For: Jul 09 - StreetInsider.comForm 8-K Trovagene, Inc. For: Jul 09 - StreetInsider.com
www.streetinsider.com - July 9 at 6:51 PM
Trovagene begins patient enrollment in early-stage colorectal cancer trial - Seeking AlphaTrovagene begins patient enrollment in early-stage colorectal cancer trial - Seeking Alpha
seekingalpha.com - July 9 at 6:51 PM
Trovagene (TROV) Commences Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer - StreetInsider.comTrovagene (TROV) Commences Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer - StreetInsider.com
www.streetinsider.com - July 9 at 8:13 AM
Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers - PRNewswireTrovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers - PRNewswire
www.prnewswire.com - July 9 at 8:13 AM
Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer CentersTrovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers
finance.yahoo.com - July 9 at 8:13 AM
Trovagene files for $150M mixed shelf; shares down 5% premarket - Seeking AlphaTrovagene files for $150M mixed shelf; shares down 5% premarket - Seeking Alpha
seekingalpha.com - June 25 at 11:59 AM
Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors - Yahoo FinanceIovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors - Yahoo Finance
finance.yahoo.com - June 11 at 7:33 PM
Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors - GlobeNewswireIovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors - GlobeNewswire
www.globenewswire.com - June 11 at 8:28 AM
Form 8-K Trovagene, Inc. For: May 30 - StreetInsider.comForm 8-K Trovagene, Inc. For: May 30 - StreetInsider.com
www.streetinsider.com - May 31 at 7:01 PM
Trovagene to Host Business Update Conference Call on June 7, 2019 - PRNewswireTrovagene to Host Business Update Conference Call on June 7, 2019 - PRNewswire
www.prnewswire.com - May 30 at 6:50 PM
Trovagene to Host Business Update Conference Call on June 7, 2019Trovagene to Host Business Update Conference Call on June 7, 2019
finance.yahoo.com - May 30 at 6:50 PM
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal Cancer - PRNewswireTrovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal Cancer - PRNewswire
www.prnewswire.com - May 23 at 7:33 PM
Trovagene (TROV) Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of Combination of Onvansertib and ONZEALD - StreetInsider.comTrovagene (TROV) Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of Combination of Onvansertib and ONZEALD - StreetInsider.com
www.streetinsider.com - May 23 at 8:15 AM
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal Cancer - Yahoo FinanceTrovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal Cancer - Yahoo Finance
finance.yahoo.com - May 23 at 8:15 AM
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal CancerTrovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal Cancer
finance.yahoo.com - May 23 at 8:15 AM
Could TrovaGene, Inc.s (NASDAQ:TROV) Investor Composition Influence The Stock Price? - Yahoo FinanceCould TrovaGene, Inc.'s (NASDAQ:TROV) Investor Composition Influence The Stock Price? - Yahoo Finance
finance.yahoo.com - May 16 at 7:53 PM
Could TrovaGene, Inc.'s (NASDAQ:TROV) Investor Composition Influence The Stock Price?Could TrovaGene, Inc.'s (NASDAQ:TROV) Investor Composition Influence The Stock Price?
finance.yahoo.com - May 16 at 7:53 PM
Trovagene up 8% on capital raise - Seeking AlphaTrovagene up 8% on capital raise - Seeking Alpha
seekingalpha.com - May 13 at 8:03 PM
Trovagene (TROV) Announces Equity Investment of $1.5 Million - StreetInsider.comTrovagene (TROV) Announces Equity Investment of $1.5 Million - StreetInsider.com
www.streetinsider.com - May 13 at 8:07 AM
Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park CapitalTrovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park Capital
finance.yahoo.com - May 13 at 8:07 AM
Trovagene Announces First Quarter 2019 Results and Highlights - PRNewswireTrovagene Announces First Quarter 2019 Results and Highlights - PRNewswire
www.prnewswire.com - May 8 at 8:13 AM
Trovagene Announces First Quarter 2019 Results and Highlights - Yahoo FinanceTrovagene Announces First Quarter 2019 Results and Highlights - Yahoo Finance
finance.yahoo.com - May 7 at 7:09 PM
Midatech Pharma leads healthcare gainers; TrovaGene and Cleveland BioLabs among losers - Seeking AlphaMidatech Pharma leads healthcare gainers; TrovaGene and Cleveland BioLabs among losers - Seeking Alpha
seekingalpha.com - April 24 at 6:44 PM
TrovaGene Proves Drug Success In Treating AML With Multiple Combinations - Seeking AlphaTrovaGene Proves Drug Success In Treating AML With Multiple Combinations - Seeking Alpha
seekingalpha.com - April 24 at 6:44 PM
Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AMLTrovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML
finance.yahoo.com - April 23 at 6:40 PM
U.S. STOCKS ON THE MOVE-Dow, Lyft, Boston Beer, Trovagene - NasdaqU.S. STOCKS ON THE MOVE-Dow, Lyft, Boston Beer, Trovagene - Nasdaq
www.nasdaq.com - April 5 at 7:57 PM
TrovaGene leads healthcare gainers; Merrimack Pharmaceuticals and Syros Pharmaceuticals among losers - Seeking AlphaTrovaGene leads healthcare gainers; Merrimack Pharmaceuticals and Syros Pharmaceuticals among losers - Seeking Alpha
seekingalpha.com - April 5 at 7:57 PM
Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib - PRNewswireTrovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib - PRNewswire
www.prnewswire.com - April 5 at 7:57 PM
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital - PRNewswireTrovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital - PRNewswire
www.prnewswire.com - April 5 at 11:11 AM
Trovagene up 16% premarket on positive onvansertib data - Seeking AlphaTrovagene up 16% premarket on positive onvansertib data - Seeking Alpha
seekingalpha.com - April 5 at 11:11 AM
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park CapitalTrovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
finance.yahoo.com - April 5 at 11:11 AM
Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of OnvansertibTrovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib
finance.yahoo.com - April 5 at 11:11 AM
Trovagene down 3% premarket on onvansertib data - Seeking AlphaTrovagene down 3% premarket on onvansertib data - Seeking Alpha
seekingalpha.com - April 3 at 8:09 PM
Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy - PRNewswireEarly Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy - PRNewswire
www.prnewswire.com - April 2 at 5:55 PM
Trovagene (TROV) presented early data from its ongoing Phase 2 study evaluating Onvansertib in combination with Zytiga/prednisone in patients with mCRPC - StreetInsider.comTrovagene (TROV) presented early data from its ongoing Phase 2 study evaluating Onvansertib in combination with Zytiga/prednisone in patients with mCRPC - StreetInsider.com
www.streetinsider.com - April 2 at 8:23 AM
Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen TherapyEarly Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy
finance.yahoo.com - April 2 at 8:23 AM
Trovagene (TROV) Reports New Data from Ongoing Phase 1b/2 Study Evaluating Onvansertib in Combination with Standard-of-Care Chemotherapy in (AML) - StreetInsider.comTrovagene (TROV) Reports New Data from Ongoing Phase 1b/2 Study Evaluating Onvansertib in Combination with Standard-of-Care Chemotherapy in (AML) - StreetInsider.com
www.streetinsider.com - April 1 at 8:05 PM
Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose LevelsPhase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels
finance.yahoo.com - April 1 at 8:05 PM
TrovaGene, Inc. Estimate MomentumTrovaGene, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 8:08 PM
Trovagene Receives Approximately $3.0 Million From Exercise of WarrantsTrovagene Receives Approximately $3.0 Million From Exercise of Warrants
finance.yahoo.com - March 13 at 7:15 PM
A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution?A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution?
finance.yahoo.com - March 13 at 8:03 AM
Trovagene Regains Compliance with Nasdaq Listing RequirementsTrovagene Regains Compliance with Nasdaq Listing Requirements
finance.yahoo.com - March 12 at 10:59 PM
Whats Behind TrovaGenes Volatile Ride?What's Behind TrovaGene's Volatile Ride?
www.benzinga.com - March 9 at 8:09 AM
Trovagene set to continue onvansertib-stoked rally, up 110% premarketTrovagene set to continue onvansertib-stoked rally, up 110% premarket
seekingalpha.com - March 8 at 7:56 PM
What Should We Expect From TrovaGene, Inc.’s (NASDAQ:TROV) Earnings Over The Next Few Years?What Should We Expect From TrovaGene, Inc.’s (NASDAQ:TROV) Earnings Over The Next Few Years?
finance.yahoo.com - March 8 at 7:56 PM
TrovaGene News: Why TROV Stock Is Skyrocketing TodayTrovaGene News: Why TROV Stock Is Skyrocketing Today
investorplace.com - March 8 at 1:22 PM
This page was last updated on 7/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel